California-based Masimo, global leader in innovative noninvasive monitoring technologies, said Cloudnine Hospital Group in Bangalore as upgraded system-wide to Masimo SET® pulse oximetry.
Congenital heart disease (CHD) is the most common birth defect and it is estimated that nearly one out of every 100 babies is born with CHD. It has been reported that around 78,000 infants die because of congenital heart disease in India every year. It occurs in one to two newborns per 1,000 live births.
“We evaluated several monitors before selecting Masimo’s superior SET® technology for all 16 Cloudnine Hospitals,” said Dr. Kishore Kumar, Chairman and Senior Neonatologist, Cloudnine Hospitals, a leader in providing premier quality healthcare to women and children in India.
“Masimo SET® will enhance our existing protocols to provide superior screening and ensure that every baby born here now has the opportunity to live a healthy life. Our hope is that universal CCHD screening become mandatory for every child born in India,” he said.
“Early detection is key in this fragile patient population,” said Joe Kiani, Founder and CEO of Masimo.
“It’s exciting to see the adoption of CCHD screening in India. Cloudnine’s hospitals have the best in class morbidity and mortality outcomes in the country – 0% maternal mortality and a 99.83% survival rate for babies. When we developed SET®, we didn’t realize how many wonderful new applications our Measure-Through Motion and Low Perfusion™ technology would make possible – so it’s especially gratifying that we can help clinicians around the world save the lives of so many babies.”
In a study of newborns, researchers have found CCHD was detected 63% of the time by standard screening and 83% of the time when screening with Masimo SET® was added. fii-news.com
